[
    {
        "source": "Upadacitinib",
        "target": "Inflammatory Bowel Disease",
        "relationship": "treats",
        "description": "Upadacitinib is used for treating inflammatory bowel disease (IBD) in patients who inadequately respond to anti-TNF-\u03b1 therapies."
    },
    {
        "source": "Risankizumab",
        "target": "Inflammatory Bowel Disease",
        "relationship": "treats",
        "description": "Risankizumab is used for treating inflammatory bowel disease (IBD) in patients who inadequately respond to anti-TNF-\u03b1 therapies."
    },
    {
        "source": "Upadacitinib",
        "target": "Crohn's Disease",
        "relationship": "treats",
        "description": "Upadacitinib is associated with the clinical response in Crohn's disease patients who are anti-TNF-\u03b1 inadequate responders."
    },
    {
        "source": "Risankizumab",
        "target": "Crohn's Disease",
        "relationship": "treats",
        "description": "Risankizumab is associated with the clinical response in Crohn's disease patients who are anti-TNF-\u03b1 inadequate responders."
    }
]